GlobeNewswire: ProQR Therapeutics N.V. Contains the last 10 of 244 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T16:43:27ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/13/2845299/0/en/ProQR-Announces-Year-End-2023-Operating-and-Financial-Results.html?f=22&fvtc=4&fvtv=23449ProQR Announces Year End 2023 Operating and Financial Results2024-03-13T11:00:00Z<![CDATA[LEIDEN, Netherlands & CAMBRIDGE, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today reported its financial and operating results for the year ended December 31, 2023, and provided a business update.]]>https://www.globenewswire.com/news-release/2024/02/15/2829825/0/en/ProQR-Announces-Japanese-Axiomer-Patent-Upheld-Following-Opposition-Against-Its-Leading-IP-Estate-for-ADAR-mediated-RNA-Editing.html?f=22&fvtc=4&fvtv=23449ProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing2024-02-15T12:00:00Z<![CDATA[LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it has successfully defended against an opposition filed in Japan against a patent directed to its ADAR-mediated RNA editing platform Axiomer™.]]>https://www.globenewswire.com/news-release/2024/01/19/2812237/0/en/ProQR-Highlights-New-Platform-Data-from-Presentation-on-Axiomer-RNA-Editing-Technology-at-Deaminet-2024.html?f=22&fvtc=4&fvtv=23449ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024 2024-01-19T12:00:00Z<![CDATA[LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan. 19, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today highlighted key updates from its oral presentation at the 5th International Conference on Base Editing, Prime Editing & Related Enzymes (Deaminet 2024) in San Diego, California.]]>https://www.globenewswire.com/news-release/2024/01/05/2804566/0/en/ProQR-and-Rett-Syndrome-Research-Trust-Join-Forces-with-Axiomer-RNA-Editing-Collaboration.html?f=22&fvtc=4&fvtv=23449ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration2024-01-05T12:00:00Z<![CDATA[LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced a collaboration with the Rett Syndrome Research Trust (RSRT) that will focus on the design and development of editing oligonucleotides (EONs) using ProQR’s Axiomer technology platform targeting the transcription factor Methyl CpG binding protein 2 (MECP2) and correcting mutations of interest.]]>https://www.globenewswire.com/news-release/2023/12/08/2793148/0/en/ProQR-Therapeutics-Announces-Transaction-Completed-for-Th%C3%A9a-to-Acquire-Sepofarsen-and-Ultevursen-Ophthalmic-Assets.html?f=22&fvtc=4&fvtv=23449ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets2023-12-08T12:30:00Z<![CDATA[Divestment of sepofarsen and ultevursen completed – Théa to continue development of sepofarsen and ultevursen for patients with LCA10 and Usher syndrome]]>https://www.globenewswire.com/news-release/2023/11/07/2774889/0/en/ProQR-Announces-Third-Quarter-2023-Operating-and-Financial-Results.html?f=22&fvtc=4&fvtv=23449ProQR Announces Third Quarter 2023 Operating and Financial Results2023-11-07T12:00:00Z<![CDATA[LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer® RNA editing technology platform, today reported its financial and operating results for the third quarter ended September 30, 2023, and provided a business update.]]>https://www.globenewswire.com/news-release/2023/11/06/2773905/0/en/ProQR-Strengthens-Leading-Intellectual-Property-Estate-for-ADAR-mediated-RNA-Editing.html?f=22&fvtc=4&fvtv=23449ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing2023-11-06T12:00:00Z<![CDATA[LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it has further strengthened its leading intellectual property (IP) estate with the issuance of a new patent in the United States and that it has successfully defended against an opposition to its IP in Japan.]]>https://www.globenewswire.com/news-release/2023/09/28/2751127/0/en/ProQR-Announces-Participation-in-the-Chardan-7th-Annual-Genetic-Medicines-Conference.html?f=22&fvtc=4&fvtv=23449ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference2023-09-28T12:00:00Z<![CDATA[LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer® RNA editing technology platform, today announced that Daniel A. de Boer, Founder and CEO, will participate in the ADAR Editing Panel at the Chardan 7th Annual Genetic Medicines Conference in New York City. The panel is scheduled for October 2, 2023 at 9:30 am – 10:15 am EDT, and a recording of the session will be made available on the Company’s website after the conference. ProQR will also participate in 1x1 investor meetings.]]>https://www.globenewswire.com/news-release/2023/09/27/2750241/0/en/ProQR-Therapeutics-Provides-Update-on-Ophthalmic-Assets.html?f=22&fvtc=4&fvtv=23449ProQR Therapeutics Provides Update on Ophthalmic Assets2023-09-27T11:00:00Z<![CDATA[LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies today provided an update that its previously announced agreement to divest the Company’s late-stage ophthalmic assets to Laboratoires Théa S.A.S. (Théa) has been terminated.]]>https://www.globenewswire.com/news-release/2023/09/07/2739243/0/en/ProQR-Announces-Webcast-of-Presentation-at-the-Upcoming-HC-Wainwright-25th-Annual-Global-Investment-Conference.html?f=22&fvtc=4&fvtv=23449ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment Conference2023-09-07T12:00:00Z<![CDATA[LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer® RNA editing technology platform, today announced that Company management will participate in the HC Wainwright 25th Annual Global Investment Conference.]]>